CY1121966T1 - Παραγωγα πεπτιδιου οπιορφινης ως ισχυροι αναστολεις εκτοπεπτιδασων αποδομησεως εγκεφαλινης - Google Patents
Παραγωγα πεπτιδιου οπιορφινης ως ισχυροι αναστολεις εκτοπεπτιδασων αποδομησεως εγκεφαλινηςInfo
- Publication number
- CY1121966T1 CY1121966T1 CY20191100256T CY191100256T CY1121966T1 CY 1121966 T1 CY1121966 T1 CY 1121966T1 CY 20191100256 T CY20191100256 T CY 20191100256T CY 191100256 T CY191100256 T CY 191100256T CY 1121966 T1 CY1121966 T1 CY 1121966T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ectopeptides
- peptide derivatives
- potent inhibitors
- opiorphin peptide
- enkephalin degradation
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 108010074283 glutaminyl-arginyl-phenylalanyl-seryl-arginine Proteins 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- TWWFCOBVAKAKIT-SXYSDOLCSA-N Opiorphin Chemical class NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)N)CC1=CC=CC=C1 TWWFCOBVAKAKIT-SXYSDOLCSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε τροποποιημένα πεπτίδια οπιορφίνης ως νέους αναστολές μεταλλο-εκτοπεπτιδασών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4292208P | 2008-04-07 | 2008-04-07 | |
| PCT/EP2009/054171 WO2009124948A1 (en) | 2008-04-07 | 2009-04-07 | Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopetidases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121966T1 true CY1121966T1 (el) | 2020-10-14 |
Family
ID=40956908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100256T CY1121966T1 (el) | 2008-04-07 | 2019-03-01 | Παραγωγα πεπτιδιου οπιορφινης ως ισχυροι αναστολεις εκτοπεπτιδασων αποδομησεως εγκεφαλινης |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8889827B2 (el) |
| EP (1) | EP2274321B1 (el) |
| JP (2) | JP5788788B2 (el) |
| KR (1) | KR20110028433A (el) |
| CN (1) | CN102083851A (el) |
| AU (1) | AU2009235484B2 (el) |
| BR (1) | BRPI0906905B1 (el) |
| CA (1) | CA2720778C (el) |
| CY (1) | CY1121966T1 (el) |
| DK (1) | DK2274321T3 (el) |
| ES (1) | ES2714374T3 (el) |
| HR (1) | HRP20190335T1 (el) |
| HU (1) | HUE042998T2 (el) |
| IL (1) | IL208543A (el) |
| LT (1) | LT2274321T (el) |
| MX (1) | MX2010011055A (el) |
| PL (1) | PL2274321T3 (el) |
| PT (1) | PT2274321T (el) |
| RU (2) | RU2542365C2 (el) |
| SI (1) | SI2274321T1 (el) |
| WO (1) | WO2009124948A1 (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
| RU2542365C2 (ru) * | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов |
| FR2931362B1 (fr) * | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2637600B1 (fr) | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
| US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
| DE60040878D1 (de) | 1999-06-23 | 2009-01-02 | Pasteur Institut | Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen |
| DE60018085T2 (de) | 2000-12-22 | 2005-07-07 | Institut Pasteur | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
| RU2223113C1 (ru) * | 2002-05-29 | 2004-02-10 | Золотарев Юрий Александрович | Пептид, обладающий регулирующей биологической активностью на белковый синтез в гепатоцитах |
| ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
| WO2008009276A1 (de) * | 2006-07-21 | 2008-01-24 | Jenoptik Laser, Optik, Systeme Gmbh | Lateral verstellbare fassung für optische elemente |
| US20100062052A1 (en) | 2007-02-02 | 2010-03-11 | Greenpharma | Peptide-based compounds as new inhibitors of metalloectopeptidases, compositions comprising said compounds and their pharmaceutical and cosmetic uses |
| WO2009090265A1 (en) | 2008-01-18 | 2009-07-23 | Institut Pasteur | Method for identifying bplp and opiorphin agonists or antagonists |
| RU2542365C2 (ru) | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов |
| FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
| CA2645452A1 (en) | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
-
2009
- 2009-04-07 RU RU2010145158/04A patent/RU2542365C2/ru active
- 2009-04-07 MX MX2010011055A patent/MX2010011055A/es active IP Right Grant
- 2009-04-07 EP EP09730759.9A patent/EP2274321B1/en active Active
- 2009-04-07 JP JP2011503426A patent/JP5788788B2/ja active Active
- 2009-04-07 PL PL09730759T patent/PL2274321T3/pl unknown
- 2009-04-07 DK DK09730759.9T patent/DK2274321T3/en active
- 2009-04-07 ES ES09730759T patent/ES2714374T3/es active Active
- 2009-04-07 LT LTEP09730759.9T patent/LT2274321T/lt unknown
- 2009-04-07 CA CA2720778A patent/CA2720778C/en active Active
- 2009-04-07 CN CN2009801212936A patent/CN102083851A/zh active Pending
- 2009-04-07 HU HUE09730759A patent/HUE042998T2/hu unknown
- 2009-04-07 BR BRPI0906905-4A patent/BRPI0906905B1/pt active IP Right Grant
- 2009-04-07 US US12/936,591 patent/US8889827B2/en active Active
- 2009-04-07 WO PCT/EP2009/054171 patent/WO2009124948A1/en active Application Filing
- 2009-04-07 SI SI200931942T patent/SI2274321T1/sl unknown
- 2009-04-07 US US12/419,426 patent/US8642729B2/en active Active
- 2009-04-07 PT PT09730759T patent/PT2274321T/pt unknown
- 2009-04-07 AU AU2009235484A patent/AU2009235484B2/en active Active
- 2009-04-07 KR KR1020107024984A patent/KR20110028433A/ko not_active Application Discontinuation
-
2010
- 2010-10-07 IL IL208543A patent/IL208543A/en active IP Right Grant
-
2014
- 2014-11-11 US US14/537,929 patent/US9273094B2/en active Active
- 2014-12-29 RU RU2014153924A patent/RU2014153924A/ru not_active Application Discontinuation
-
2015
- 2015-02-23 JP JP2015032997A patent/JP2015110651A/ja active Pending
-
2019
- 2019-02-20 HR HRP20190335TT patent/HRP20190335T1/hr unknown
- 2019-03-01 CY CY20191100256T patent/CY1121966T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124924T1 (el) | Φαρμακευτικη συνθεση καρβετοκινης | |
| CY1123865T1 (el) | Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου | |
| CY1122639T1 (el) | Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| NO20084334L (no) | Farmasoytiske sammensetninger | |
| UA118167C2 (uk) | Пептид та його застосування | |
| EA201171494A1 (ru) | Миметики белка smac | |
| CY1122794T1 (el) | Συνθεσεις αλφα-γαλακτοσιδασης | |
| EA201290772A1 (ru) | Новые формы ивабрадина гидрохлорида | |
| UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
| MA32938B1 (fr) | Composes organiques | |
| DK2389382T3 (da) | Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer | |
| ME01665B (me) | Analozi buprenorfina | |
| BRPI0922913A2 (pt) | Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral | |
| MA32562B1 (fr) | Composes organiques pour la cicatrisation de lesion | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| CL2007002182S1 (es) | Terminal. | |
| BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
| CY1114983T1 (el) | Συνθεση για τη θεραπεια της κυστικης ινωσης | |
| CY1121966T1 (el) | Παραγωγα πεπτιδιου οπιορφινης ως ισχυροι αναστολεις εκτοπεπτιδασων αποδομησεως εγκεφαλινης | |
| UA108636C2 (xx) | Пептид | |
| CY1117086T1 (el) | Νεος συνδυασμος | |
| UA107476C2 (uk) | Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів | |
| CY1119468T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη | |
| CY1115714T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια της πολλαπλης σκληρυνσης |